Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma

WEST HOLLYWOOD, Calif., Dec. 20, 2022, ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only methylprednisolone (MP) well tolerated and shows efficacy for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials